A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...

Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...

This webinar provides a clear-eyed assessment of current hiring conditions across biopharma, exploring which roles and skills ...

The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission ...

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a ...

Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” ...

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

As the field grows rapidly, companies are luring people from other nuclear industries and tapping the expanding educational ...

As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...